Clinical trial
A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation
NCT06959095 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 20, 2025
- Completion date
- February 14, 2029
- Enrollment
- 981 (estimated)
- Sites
- 281
Conditions
As the registry lists them; a condition with its own page is linked.